Baird analyst Brian Skorney weighs in on the Sarepta (SRPT +1.4%) debate today, saying that...

Baird analyst Brian Skorney weighs in on the Sarepta (SRPT +1.4%) debate today, saying that management is firm on its guidance for a breakthrough designation on Eteplirsen. Skorney notes that SRPT will be deciding on its strategy within the few months. Traders aren't so sure however, as short interest has gone from a low of 1.4% in July 2012, up to 33.5% through the middle of this month, while the average days to cover has jumped to over 10.
From other sites
Comments (3)
  • malcolmnewton
    , contributor
    Comments (14) | Send Message
    SRPT. There is very little stock available to buy.
    Anyone short will have a real problem trying to buy any volume.
    If there are 9 million shares short then this is going be a
    phenomenal squeeze at some point.
    It is thinly traded around a million shares a day.
    Covering will probably drive it over $60 imo.
    26 Jun 2013, 01:06 PM Reply Like
  • GaryLee276
    , contributor
    Comments (152) | Send Message
    26 Jun 2013, 01:10 PM Reply Like
  • domitrix
    , contributor
    Comments (5) | Send Message
    If you understand the science first, then the politics, then this is one stock that would never be shorted.
    26 Jun 2013, 05:41 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs